Presentation TCT 2015 Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease Presenter: Bernard J. Gersh, Stephen D. Wiviott, Giora Weisz October 13, 2015
Presentation TCT 2015 Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why? Presenter: Bernard J. Gersh, Stephen D. Wiviott October 13, 2015
Presentation TCT 2015 PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events Presenter: Bernard J. Gersh, Stephen D. Wiviott, Evan A. Stein October 13, 2015
Presentation TCT 2015 Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic? Presenter: Bernard J. Gersh, Stephen D. Wiviott, David J. Maron October 13, 2015
Presentation TCT 2015 Does PEGASUS Inform the Debate? Presenter: John A. Bittl, Gary L. Schaer, Stephen D. Wiviott October 12, 2015
News Daily News Prasugrel Efficacy in STEMI Largely Unaffected by PCI Timing Yael L. Maxwell June 17, 2014
News Daily News TRILOGY ACS Substudy: Prasugrel Post-Angiography Minimizes Risk of Adverse Events Yael L. Maxwell August 23, 2013
News Daily News Subestudio del TRILOGY ACS: El Prasugrel Post-Angiografía Minimiza el Riesgo de Episodios Adversos Yael L. Maxwell August 23, 2013
Presentation Prasugrel vs. Clopidogrel for Patients with Unstable Angina or NSTEMI With or Without Angiography Presenter: Stephen D. Wiviott August 20, 2013
News Conference News TCT 2012 TRILOGY ACS Substudy: Angiography Prior to Prasugrel Therapy Reduces CV Events October 25, 2012
Presentation TCT 2012 TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After... Presenter: Stephen Wiviott October 24, 2012
News Industry News Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome October 24, 2012
News Daily News High Platelet Reactivity Predicts Poor Outcomes, Routine Testing Still Debated Jason Kahn October 24, 2011
News Industry News Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study August 15, 2011
News Daily News LANCELOT: Antiplatelet Agent Shows Positive Signs in Patients With ACS, Stable CAD Jason Kahn April 21, 2011